EGFR
Clinical trials for EGFR explained in plain language.
Never miss a new study
Get alerted when new EGFR trials appear
Sign up with your email to follow new studies for EGFR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients when standard pills fail
Disease control Recruiting nowThis study is for people with a common type of advanced lung cancer (non-small cell) that has stopped responding to a class of targeted pills called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug (befotertinib),…
Matched conditions: EGFR
Phase: PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New drug EPI-326 takes on tough cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR mutation) or head/neck cancer. The main goals are to check safety and find the best dose. About 110 participants will receive the drug to see if it can shrink tumors a…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New hope for hard-to-treat cancers? first human trial begins
Disease control Recruiting nowThis study tests a new experimental drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have spread or cannot be removed. The goal is to find safe doses and see if the drug can shrink tumors. About 450 adults with cer…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New pill shows promise against tough lung cancer mutations in phase 3 trial
Disease control Recruiting nowThis study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has specific EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is …
Matched conditions: EGFR
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC